Study of TOP1630 for Dry Eye Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

202 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-13

Study Completion Date

2019-05-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In subjects with Dry Eye Syndrome (DES):

The primary objective of this study is to confirm the efficacy of TOP1630 0.1% Ophthalmic Solution TID OU compared to placebo treatment at Day 29 on pre-specified sign and symptom endpoints in subjects with moderate to severe DES.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of TOP1630 for Dry Eye Syndrome

NCT03088605

Dry Eye Syndrome

COMPLETED PHASE2

A Clinical Trial to Assess Subjects With Dry Eye Disease.

NCT04971031

Dry Eye

COMPLETED PHASE2

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

NCT04735393

Dry Eye Disease

COMPLETED PHASE3

A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

NCT06493604

Dry Eye Disease

COMPLETED PHASE3

A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

NCT03162783

Dry Eye Syndromes

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is designed to assess the efficacy and safety of TOP1630 ophthalmic solution in subjects with Dry Eye Syndrome (DES).

Eligible subjects will be randomized double masked to either TOP1630 or placebo for a duration of 28 days' treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TOP1630 Ophthalmic Solution

Group Type EXPERIMENTAL

TOP1630 0.1% Ophthalmic Solution TID OU

Intervention Type DRUG

Bilateral ocular drug administration

Placebo to TOP1630 Ophthalmic Solution

Group Type PLACEBO_COMPARATOR

Placebo to TOP1630 0.1% Ophthalmic Solution TID OU

Intervention Type DRUG

Bilateral ocular drug administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TOP1630 0.1% Ophthalmic Solution TID OU

Bilateral ocular drug administration

Intervention Type DRUG

Placebo to TOP1630 0.1% Ophthalmic Solution TID OU

Bilateral ocular drug administration

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be at least 18 years of age;
* Provide written informed consent;
* Have a reported history of dry eye;
* Have a history of use of eye drops for dry eye symptoms;

Symptoms of dry eye syndrome including:

* Ocular discomfort
* Conjunctival redness
* Tear film break up time
* Schirmer test score

Signs of dry eye syndrome including:

* Conjunctival staining score

Exclusion Criteria

* Have any clinically significant slit lamp findings at entry visit ;
* Be diagnosed with an ongoing ocular infection;
* Have any significant ocular lesion that could interfere with assessment of safety or efficacy or prevent study conduct in the opinion of the PI;
* Have any planned ocular and/or lid surgeries over the study period;
* Have an uncontrolled systemic disease;
* Be a woman who is pregnant, nursing or planning a pregnancy;
* Be a woman of childbearing potential who is not using an acceptable means of birth control;
* Have a known allergy and/or sensitivity to the test article or its components;
* Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No